CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

4D Molecular Therapeutics Collaborates with Leading Machine Learning Technology Experts

Life Sciences Review Life Sciences Review | Thursday, May 20, 2021
Tweet

The partnership with Drs. Listgarten and Schaffer empower 4DMT to expand its bioinformatics capabilities, enabling it to find promising vectors both within and beyond existing libraries.


FREMONT, CA: 4D Molecular Therapeutics, a clinical-stage gene therapy firm harnessing the power of directed evolution for targeted gene therapies, collaborates with investigators at the University of California, Berkeley focused on widening the vector invention power of 4DMTs Therapeutic Vector Evolution platform by applying machine learning to the AAV vector capsid datasets created from 4DMTs platform. This research will be performed with Jennifer Listgarten, Ph.D., a leader in machine learning and computational biology, and David Schaffer, Ph.D., a global leader in AAV-directed evolution and gene therapy.


This cross-functional partnership with world leaders in machine learning and AAV gene therapy technologies offers the potential to dramatically expand the depth and breadth of targeted and evolved vectors invented through the Therapeutic Vector Evolution platform, expanding the company’s vector patent and product portfolios. 4DMTs industry-leading AAV capsid libraries encompass over one billion synthetic capsid sequences. 


The company has the largest capsid biodistribution datasets in the world due to the over 15 vector selection programs conducted in non-human primates. This partnership reaffirms its commitment to relentless innovation to bring cures to patients.


Therapeutic Vector Evolution combines the power of directed evolution with approximately one billion synthetic capsid sequences to find evolved vectors for use in targeted gene therapy products. Using its proprietary Therapeutic Vector Evolution platform, to date, 4DMT has produced an industry-leading 40 distinct capsid libraries, conducted more than 15 vector selections in non-human primates, and has filed patent applications on over 300 new AAV vectors. The application of machine learning to 4DMTs Therapeutic Vector Evolution and its datasets illustrates an opportunity to enable technology to invent new vectors for targeted gene therapy products.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/4d-molecular-therapeutics-collaborates-with-leading-machine-learning-technology-experts-nwid-370.html